Retatrutide is a novel investigational peptide that functions as a triple receptor agonist targeting GLP-1 , GIP , and glucagon receptors
Perspectives and conclusions Tirzepatide has demonstrated marked and dose-dependent reductions in glycemic parameters in patients with T2D that, according to the present study data, surpass the effects of the GLP-1RA dulaglutide and semaglutide (54, 66, 67, 71)
Since it remains under investigation, its long-term safety and efficacy will require continued scrutiny as more patients experience it and more evidence is accrued
Each stage must scale efficiently to support large commercial production campaigns
Many women experience menstrual irregularities during the first 3-6 months of treatment
This framework does not permit the general supply or self-sourcing of unlicensed injectable preparations